Fig. 3: Progression-free survival in patients with glioblastoma treated with chemoradiotherapy and glasdegib. | Nature Communications

Fig. 3: Progression-free survival in patients with glioblastoma treated with chemoradiotherapy and glasdegib.

From: Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial

Fig. 3: Progression-free survival in patients with glioblastoma treated with chemoradiotherapy and glasdegib.The alternative text for this image may have been generated using AI.

a Kaplan-Meier graph showing progression-free survival in the treated population. b Kaplan-Meier graph showing progression-free survival stratified by MGMT promoter methylation status. A Cox hazard model (two sided) was used for the statistical comparison between the subgroups (exploratory analysis). The shadowed areas represent the 95% CI. The dotted lines signal the 50% probability of the PFS. c Forest plot showing hazard ratios for progression or death in the analysis of treatment effect in patient subgroups according to baseline characteristics using a Cox hazard model (two sided, exploratory analysis). n indicates the number of patients with events over the total number of patients in each subgroup (N). Whiskers represent 95% CI.

Back to article page